BioMarin Pharmaceutical Inc. (LON:0HNC)

Market Cap	8.94B
Revenue (ttm)	2.28B
Net Income (ttm)	340.96M
Shares Out	n/a
EPS (ttm)	1.76
PE Ratio	26.23
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33
Average Volume	266
Open	58.00
Previous Close	58.86
Day's Range	58.00 - 59.32
52-Week Range	58.00 - 99.65
Beta	n/a
RSI	40.74
Earnings Date	Apr 25, 2025

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1996
• Employees: 3,040
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HNC

Financial Performance

In 2024, BioMarin Pharmaceutical's revenue was $2.85 billion, an increase of 17.97% compared to the previous year's $2.42 billion. Earnings were $426.86 million, an increase of 154.62%.

Financial numbers in USD